Abstract
In humans, glucocorticoid excess may cause neuropsychiatric symptoms, including psychosis and cognitive impairment, and glucocorticoid signaling hyperactivation may sensitize to substance of abuse. The aim of this work was to evaluate whether exposure to glucocorticoid excess triggers molecular changes in dopaminergic and opioidergic systems within relevant forebrain areas. We acutely exposed Sprague-Dawley rats to dexamethasone, a glucocorticoid analog, or vehicle and evaluated the mRNA expression of dopamine D1 and D2 receptors and enkephalin within the cortex, the striatum, and the midbrain.
Dexamethasone reduced mRNA expression of D1 receptor and enkephalin in the cortex. In the striatum, dexamethasone reduced the expression of D1 receptor mRNA, but not that of D2 receptor and enkephalin. No significant changes in D2 receptor mRNA expression were observed in the midbrain. Basal distribution of D1 and D2 receptor mRNA showed a clear-cut striatal/cortical gradient, while this distribution was less obvious for enkephalin mRNA. Dexamethasone increased the cortico-striatal separation in terms of D1 and D2 receptor mRNA expression.
These molecular changes may represent adaptive mechanisms to dexamethasone-induced potentiation of dopaminergic and opioidergic transmission, mostly in cortical areas.
Keywords: Cognition, cortex, cortisol, dexamethasone, gene expression, glucocorticoid, schizophrenia, striatum.
Current Molecular Pharmacology
Title:The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico- Subcortical Regions
Volume: 6
Author(s): Felice Iasevoli, Luigi Aloj, Gianmarco Latte, Livia Avvisati, Federica Marmo, Carmine Tomasetti, Elisabetta F. Buonaguro, Chiara Simeoli, Rosario Pivonello, Annamaria Colao and Andrea de Bartolomeis
Affiliation:
Keywords: Cognition, cortex, cortisol, dexamethasone, gene expression, glucocorticoid, schizophrenia, striatum.
Abstract: In humans, glucocorticoid excess may cause neuropsychiatric symptoms, including psychosis and cognitive impairment, and glucocorticoid signaling hyperactivation may sensitize to substance of abuse. The aim of this work was to evaluate whether exposure to glucocorticoid excess triggers molecular changes in dopaminergic and opioidergic systems within relevant forebrain areas. We acutely exposed Sprague-Dawley rats to dexamethasone, a glucocorticoid analog, or vehicle and evaluated the mRNA expression of dopamine D1 and D2 receptors and enkephalin within the cortex, the striatum, and the midbrain.
Dexamethasone reduced mRNA expression of D1 receptor and enkephalin in the cortex. In the striatum, dexamethasone reduced the expression of D1 receptor mRNA, but not that of D2 receptor and enkephalin. No significant changes in D2 receptor mRNA expression were observed in the midbrain. Basal distribution of D1 and D2 receptor mRNA showed a clear-cut striatal/cortical gradient, while this distribution was less obvious for enkephalin mRNA. Dexamethasone increased the cortico-striatal separation in terms of D1 and D2 receptor mRNA expression.
These molecular changes may represent adaptive mechanisms to dexamethasone-induced potentiation of dopaminergic and opioidergic transmission, mostly in cortical areas.
Export Options
About this article
Cite this article as:
Iasevoli Felice, Aloj Luigi, Latte Gianmarco, Avvisati Livia, Marmo Federica, Tomasetti Carmine, Buonaguro F. Elisabetta, Simeoli Chiara, Pivonello Rosario, Colao Annamaria and Bartolomeis de Andrea, The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico- Subcortical Regions, Current Molecular Pharmacology 2013; 6 (3) . https://dx.doi.org/10.2174/187446720603140415215941
DOI https://dx.doi.org/10.2174/187446720603140415215941 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemical Communication-Do We Have a Quorum?
Mini-Reviews in Medicinal Chemistry Pathogenesis and Subtype of Intracerebral Hemorrhage (ICH) and ICH Score Determines Prognosis
Current Neurovascular Research Signal Transduction of Radiation and/or Hyperthermic Cancer Therapies
Current Signal Transduction Therapy Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
Current Neuropharmacology Proposition of Potential GSK-3β Inhibitors for the Treatment of Alzheimer’s Disease: A Molecular Modeling Study
Current Computer-Aided Drug Design Evidence Linking Protein Misfolding to Quality Control in Progressive Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities
Current Pharmaceutical Design Molecular Mechanisms of Anti-Inflammatory Activity Mediated by Flavonoids
Current Medicinal Chemistry An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Plant Plastid Engineering
Current Genomics Towards a Reconceptualization of Striatal Interactions Between Glutamatergic and Dopaminergic Neurotransmission and Their Contribution to the Production of Movements
Current Neuropharmacology γ-Secretase as a Therapeutic Target for Treatment of Alzheimers Disease
Current Pharmaceutical Design Role of Nitric Oxide in Neurodegeneration: Function, Regulation, and Inhibition
Current Neuropharmacology Off-Label Trazodone Prescription: Evidence, Benefits and Risks
Current Pharmaceutical Design ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry ERRATUM
Current Neuropharmacology Patient Education and Telemedicine in COPD - Update 2015
Current Respiratory Medicine Reviews Natural Polyphenols in the Treatment of Alzheimer’s Disease
Current Drug Targets Withdrawal Notice: Neuroprotective Effect of Lithospermum officinale callus Extract on Inflamed Primary Microglial Cells
Current Pharmaceutical Biotechnology An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band
Current Alzheimer Research